A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

NCT05510245 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
18
Enrollment
INDUSTRY
Sponsor class

Stopped The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.

Conditions

Interventions

Sponsor

Pfizer